Changing from bevacizumab to ranibizumab in age-related macular degeneration. Is it safe?

QR Code

Changing from bevacizumab to ranibizumab in age-related macular degeneration. Is it safe?

Dimitrios A Karagiannis1, Ioannis D Ladas2, Efstratios Parikakis1, Ilias Georgalas2, Athanasios Kotsolis2, Giorgos Amariotakis1, Vasileios Soumplis1, Panagiotis Mitropoulos11Ophthalmiatrio Eye Hospital of Athens, Athens, Greece; 2First Department of Ophthalmology, Medical School of Athens University...

Full description

Saved in:

Bibliographic Details
Main Authors:	Dimitrios A Karagiannis, Ioannis D Ladas, Efstratios Parikakis, et al.
Format:	article
Language:	EN
Published:	Dove Medical Press 2009
Subjects:	Age related macular degeneration Bevacizumab Ranimizumab subretinal haemorrhage Geriatrics RC952-954.6
Online Access:	https://doaj.org/article/5b4a909ac95b4d3da9972cb7c9110698
Tags:	Add Tag No Tags, Be the first to tag this record!

Similar Items

Subretinal Injection of Recombinant Tissue Plasminogen Activator and Gas Tamponade to Displace Acute Submacular Haemorrhages Secondary to Age-Related Macular Degeneration
by: Iannetta D, et al.
Published: (2021)

Location of submacular hemorrhage as a predictor of visual outcome after intravitreal ranibizumab for age-related macular degeneration
by: Karagiannis D, et al.
Published: (2017)

Long-term effectiveness of ranibizumab for age-related macular degeneration and diabetic macular edema
by: Fong AH, et al.
Published: (2013)

Full-thickness macular hole formation following anti-VEGF injections for neovascular age-related macular degeneration
by: Kabanarou SA, et al.
Published: (2017)

Inner Retinal Layer Thickness Alterations in Early Age Related Macular Degeneration in Eyes with Subretinal Drusenoid Deposits or Conventional Drusen
by: Solmaz Abdolrahimzadeh, et al.
Published: (2021)

Visual outcome of intravitreal ranibizumab for exudative age-related macular degeneration: timing and prognosis
by: Canan H, et al.
Published: (2014)

Intravitreal Ranibizumab or Aflibercept After Bevacizumab in Diabetic Macular Edema: Exploratory Retrospective Analysis
by: Pessoa B, et al.
Published: (2021)

Effects of intravitreal ranibizumab on the untreated eye and systemic gene expression profile in age-related macular degeneration
by: Michalska-Małecka K, et al.
Published: (2016)

Anatomical and functional response after conversion to aflibercept using the treat-and-extend regimen protocol in bevacizumab treatment-resistant wet age-related macular degeneration
by: Taipale C, et al.
Published: (2018)

Recent developments in age-related macular degeneration: a review
by: Al-Zamil WM, et al.
Published: (2017)

A case of subretinal neovascularization treated with intravitreal ranibizumab in a patient with idiopathic juxtafoveal retinal telangiectasis
by: Dimitrios Karagiannis, et al.
Published: (2008)

Stem cell therapies for age-related macular degeneration: the past, present, and future
by: Dang Y, et al.
Published: (2015)

Acquired Vitelliform Macular Degeneration: Characteristics and Challenges of Managing Subretinal Fluid
by: Joseph Juliano, et al.
Published: (2021)

Five-year outcomes of intravitreal drug therapy for neovascular age-related macular degeneration in eyes with baseline vision 20/60 or better
by: Khanani AM, et al.
Published: (2019)

Lower cognitive function in patients with age-related macular degeneration: a meta-analysis
by: Zhou LX, et al.
Published: (2016)

Spotlight on reticular pseudodrusen
by: Rabiolo A, et al.
Published: (2017)

Primary treatment of diabetic macular edema
by: Tushar M Ranchod, et al.
Published: (2009)

Macular morphology and response to ranibizumab treatment in patients with wet age-related macular degeneration
by: Dervenis N, et al.
Published: (2016)

Implantation of the First IMT Macular Lens in Age-Related Macular Degeneration (Literature Review)
by: M. M. Bikbov, et al.
Published: (2019)

Bevacizumab treatment in the elderly patient with metastatic colorectal cancer
by: Di Bartolomeo M, et al.
Published: (2015)

Early and intermediate age-related macular degeneration: update and clinical review
by: García-Layana A, et al.
Published: (2017)

The outcome of low-frequency intravitreal bevacizumab therapy for macular edema in retinal vein occlusions
by: Ivanovska Adjievska B, et al.
Published: (2017)

The cGAS/STING pathway: a sensor of senescence-associated DNA damage and trigger of inflammation in early age-related macular degeneration
by: Wu Y, et al.
Published: (2019)

Gene expression levels of the insulin-like growth factor family in patients with AMD before and after ranibizumab intravitreal injections
by: Strzalka-Mrozik B, et al.
Published: (2017)

Contralateral eye-to-eye comparison of intravitreal ranibizumab and a sustained-release dexamethasone intravitreal implant in recalcitrant diabetic macular edema
by: Thomas BJ, et al.
Published: (2016)

Evaluation Of The Timing Of Intravitreal Bevacizumab Injection As Adjuvant Therapy To Panretinal Photocoagulation In Patients With Diabetic Macular Edema Secondary To Diabetic Retinopathy
by: Kartasasmita A, et al.
Published: (2019)

Management of neovascular age-related macular degeneration: Taiwan expert consensus
by: Ling Yeung, et al.
Published: (2021)

Combination verteporfin photodynamic therapy ranibizumab-dexamethasone in choroidal neovascularization due to age-related macular degeneration: results of a phase II randomized trial
by: Gallemore RP, et al.
Published: (2017)

The effect of vitreomacular adhesion in exudative age-related macular degeneration on the results of ranibizumab intravitreal injection
by: Suzuki H, et al.
Published: (2017)

Cost-Effectiveness of Conbercept vs. Ranibizumab for Age-Related Macular Degeneration, Diabetic Macular Edema, and Pathological Myopia: Population-Based Cohort Study and Markov Model
by: Zhuang Cui, et al.
Published: (2021)

Neovascular age-related macular degeneration: intraocular inflammatory cytokines in the poor responder to ranibizumab treatment
by: Pongsachareonnont P, et al.
Published: (2018)

Effects of Intravitreal Bevacizumab Therapy in Patients with Proliferative Diabetic Retinopathy
by: Ribeiro de Carvalho G, et al.
Published: (2020)

Real-World Visual And Clinical Outcomes For Patients With Neovascular Age-Related Macular Degeneration Treated With Intravitreal Ranibizumab: An 8-Year Observational Cohort (AMD8)
by: Horner F, et al.
Published: (2019)

Microcurrent stimulation in the treatment of dry and wet macular degeneration
by: Chaikin L, et al.
Published: (2015)

Photobiomodulation Therapy for Age-Related Macular Degeneration and Diabetic Retinopathy: A Review
by: Muste JC, et al.
Published: (2021)

Long-Term Ranibizumab Treatment in Neovascular Age-Related Macular Degeneration: A Belgian Subanalysis from the Global Real-World LUMINOUSTM Study
by: Leys AM, et al.
Published: (2020)

Optimized Prediction Models from Fundus Imaging and Genetics for Late Age-Related Macular Degeneration
by: Arun Govindaiah, et al.
Published: (2021)

A retrospective study of the real-life utilization and effectiveness of ranibizumab therapy for neovascular age-related macular degeneration in the UK
by: Hykin P, et al.
Published: (2016)

Long-term outcomes of intravitreous bevacizumab or tissue plasminogen activator or vitrectomy for macular edema due to branch retinal vein occlusion
by: Kumagai K, et al.
Published: (2019)

Comparison between intravitreal bevacizumab and posterior sub-tenon injection of triamcinolone acetonide in macular edema secondary to retinal vein occlusion
by: Tsai MJ, et al.
Published: (2018)